Drugs / JMKX000623
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06066060 | Sep → Nov 2023 | — | Jemincare | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06221241 | Mar 2024 → Mar 2025 | diabetic polyneuropathy | Jemincare | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JMKX000623 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06066060 ↗ |
| Route | Oral | “administered orally” NCT06066060 ↗ |